Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Adjuvanted multi-epitope vaccines protect HLA-A*11:01 transgenic mice against Toxoplasma gondii
Kamal El Bissati, … , Craig W. Roberts, Rima McLeod
Kamal El Bissati, … , Craig W. Roberts, Rima McLeod
Published September 22, 2016
Citation Information: JCI Insight. 2016;1(15):e85955. https://doi.org/10.1172/jci.insight.85955.
View: Text | PDF
Research Article Vaccines

Adjuvanted multi-epitope vaccines protect HLA-A*11:01 transgenic mice against Toxoplasma gondii

  • Text
  • PDF
Abstract

We created and tested multi-epitope DNA or protein vaccines with TLR4 ligand emulsion adjuvant (gluco glucopyranosyl lipid adjuvant in a stable emulsion [GLA-SE]) for their ability to protect against Toxoplasma gondii in HLA transgenic mice. Our constructs each included 5 of our best down-selected CD8+ T cell–eliciting epitopes, a universal CD4+ helper T lymphocyte epitope (PADRE), and a secretory signal, all arranged for optimal MHC-I presentation. Their capacity to elicit immune and protective responses was studied using immunization of HLA-A*11:01 transgenic mice. These multi-epitope vaccines increased memory CD8+ T cells that produced IFN-γ and protected mice against parasite burden when challenged with T. gondii. Endocytosis of emulsion-trapped protein and cross presentation of the antigens must account for the immunogenicity of our adjuvanted protein. Thus, our work creates an adjuvanted platform assembly of peptides resulting in cross presentation of CD8+ T cell–eliciting epitopes in a vaccine that prevents toxoplasmosis.

Authors

Kamal El Bissati, Aziz A. Chentoufi, Paulette A. Krishack, Ying Zhou, Stuart Woods, Jitender P. Dubey, Lo Vang, Joseph Lykins, Kate E. Broderick, Ernest Mui, Yasuhiro Suzuki, Qila Sa, Stephanie Bi, Nestor Cardona, Shiv K. Verma, Laura Fraczek, Catherine A. Reardon, John Sidney, Jeff Alexander, Alessandro Sette, Tom Vedvick, Chris Fox, Jeffrey A. Guderian, Steven Reed, Craig W. Roberts, Rima McLeod

×

Figure 4

LO and AZ elicit specific immune responses in HLA-A03 seropositive and seronegative donors.

Options: View larger image (or click on image) Download as PowerPoint
LO and AZ elicit specific immune responses in HLA-A03 seropositive and s...
(A–C) ELISpot showing IFN-γ spot formation. PBMCs were tested using LO, AZ, and pool of peptides. (C) Con A and TLA were used as controls. Variability between determinations for single donors are shown in panels A and B with n = 6 determinations (as described in Figure 1). In A and B, the data shown are a single representative experiment from one T. gondii seropositive and one T. gondii seronegative HLA-A03-supertype donor. Each experiment was carried out with 6 determinations. Replicate experiments also were performed 3 times with PBMCs from 3 T. gondii seropositive and 3 T. gondii seronegative HLA-A03 individuals. Two-tailed Student’s t test was used for statistical analysis comparing differences between the 2 groups (n = 3 per group, P < 0.05). One-way ANOVA was performed before the Student’s t test to determine whether there was an overall difference between the groups. Differences between the stimulation of seropositive and seronegative individuals’ PBMCs by the poly-epitope proteins were significant (P < 0.05, data not shown). Similarly, TLA stimulated the seropositive persons’ PBMCs, but Con A did not (data not shown).

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts